---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-083169"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T07:59:55.620296+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q2 royalties up 7% to $111.7M; acquires Entasis, agrees to buy La Jolla

## Summary
- Royalties increased 7% to $111.7M in Q2 2022 vs Q2 2021.
- Income from operations decreased 14% to $82.6M due to Entasis consolidation.
- Completed acquisition of remaining ~40% of Entasis for $2.20/share ($42M total).
- Entered merger to acquire La Jolla Pharmaceutical for $6.23/share (~$149M enterprise value).
- Sold 15% stake in Theravance Respiratory Co. to Royalty Pharma for ~$282M upfront plus potential $50M milestone.

## SEC filing metadata
- accession: 0001104659-22-083169
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465922083169/0001104659-22-083169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465922083169/tm2221883d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-083169
- JSON: https://secwatch.observer/filing/0001104659-22-083169.json
- Plain text: https://secwatch.observer/filing/0001104659-22-083169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.